We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

22 hedge funds and large institutions have $16M invested in NeuBase Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

66% more capital invested

Capital invested by funds: $9.62M → $16M (+$6.34M)

38% more funds holding

Funds holding: 16 → 22 (+6)

Holders
22
Holders Change
+6
Holders Change %
+37.5%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EI
EAM Investors
California
+$586K
2
Renaissance Technologies
Renaissance Technologies
New York
+$561K
3
BlackRock
BlackRock
New York
+$184K
4
Millennium Management
Millennium Management
New York
+$168K
5
JP Morgan Chase
JP Morgan Chase
New York
+$80.6K

Top Sellers

Rank Fund Capital Flow
1
FIA
FNY Investment Advisers
New York
-$97.6K
2
VF
Virtu Financial
New York
-$64K
3
UBS Group
UBS Group
Switzerland
-$19.9K
4
Bank of America
Bank of America
North Carolina
-$1K
5
First Manhattan
First Manhattan
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
26
Parallel Advisors
California
– -$1K -6 Closed
1
2

NBSE Hedge Fund Activity: Q4 2019 in Review

22 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2019, worth a combined $16M — up 66% from $9.62M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NBSE positions and 4 closed out — a net gain of 6 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $586K. The largest seller was FNY Investment Advisers, cutting an estimated $97.6K.

  • 22 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2019, up from 16 in Q3 2019.
  • Funds reported $16M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2019, up 66% quarter-over-quarter.
  • 10 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2019 and 4 closed out, a net change of +6 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2019 was EAM Investors, an estimated $586K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2019 was FNY Investment Advisers, an estimated $97.6K sold.

Based on aggregated 13F filings for Q4 2019.